Diagnosis of neuro-endocrine carcinoma of the gynecological tract

Clinical trials for Diagnosis of neuro-endocrine carcinoma of the gynecological tract explained in plain language.

Never miss a new study

Get alerted when new Diagnosis of neuro-endocrine carcinoma of the gynecological tract trials appear

Sign up with your email to follow new studies for Diagnosis of neuro-endocrine carcinoma of the gynecological tract, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a lung cancer drug tackle a rare, aggressive gynecological cancer?

Disease control Not yet recruiting

This phase II trial is testing whether tarlatamab, an immunotherapy drug already used for small cell lung cancer, can help people with recurrent gynecological neuroendocrine carcinoma—a rare and aggressive cancer of the cervix, vulva, or vagina. The drug works by guiding the body…

Matched conditions: DIAGNOSIS OF NEURO-ENDOCRINE CARCINOMA OF THE GYNECOLOGICAL TRACT

Phase 2 • Sponsor: University Hospital, Strasbourg, France • Aim: Disease control

Last updated Aug 28, 2026 00:00 UTC

Diagnosis of neuro-endocrine carcinoma of the gynecological tract

Get alerted when new Diagnosis of neuro-endocrine carcinoma of the gynecological tract trials appear

Can a lung cancer drug tackle a rare, aggressive gynecological cancer?